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Skin rash is one of the notorious adverse events of gefitinib as well as other epidermal growth factor receptor
tyrosine kinase inhibitors. The differences of response rate and frequency of adverse events between ethnic groups
are well known. Some reports demonstrated the correlation between development of rash and efficacy in
Caucasian patients treated with erlotinib, gefitinib or cetuximab. We analyzed clinical course of Japanese patients of
lung adenocarcinoma in order to assess the relation between adverse events and efficacy of gefitinib. Between
January 2008 and June 2012, 24 Japanese patients administered gefitinib 250 mg daily. The adverse events were
evaluated in accordance with Common Terminology Criteria For Adverse Events v4.0 (CTCAE). Objective response
to gefitinib was evaluated with using computed tomography every 1–2 months. The relationship between each
adverse event and objective response was examined by chi-square test. The Log-rank Test was used to assess the
relationship between the presence of skin rash and overall survival. Twenty four patients with a median age of 67
years (range 55–89) entered were 16 female and 8 male patients; the pathological diagnosis of all patients was
adenocarcinoma. Skin rash in CTCAE occurred in 10. The objective response and overall survival among the patients
with skin rash was significantly superior to the patients without skin rash. Skin rash by gefitinib correlates with
improved clinical outcomes among advanced lung adenocarcinoma patients.
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Gefitinib has been already the first line treatment as one
of the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKI) for lung adenocarcinoma cancer
with EGFR mutation (Keedy et al. 2011). EGFR mutation
was found to be statistically significantly more frequent
in patients of East Asian origin versus other ethnicities
(30 versus 8%) (Shigematsu et al. 2005). Therefore, the
percentage of responders to EGFR-TKI almost paralleled
the percentage of patients with EGFR mutations (Jiang
2009; Kris et al. 2003, Sequist et al. 2008; Tamura et al.
2008). On the other hand, interstitial lung disease (ILD)
has been reported in Japanese NSCLC patients receiving
gefitinib at higher rates than outside Japan (Ando et al.
2006; Kudoh et al. 2008; Park and Goto 2006). Because* Correspondence: yasoos@hotmail.com
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in any medium, provided the original work is pILD induced by gefitinib is high mortality, the ethnic dif-
ferences of ILD induced by gefitinib is reported well.
Although the data of Fukuoka et al. have shown that the
adverse event profile for gefitinib in Asia and non-Asia
patients is similar (Fukuoka et al. 2003), the relationship
between the efficacy and adverse events of gefitinib in
the respect of the ethnic differences are still unclear.
EGFR-TKI causes different adverse events from other
anti-cancer agents, though molecular targeted anti-
cancer drug was expected to be less harm than the other
cytotoxic anti-cancer drugs (Forsythe and Faulkner
2004). Indeed, cytotoxic adverse events such as myelo-
suppression occur in lower rate (Kim et al. 2008;
Thatcher et al. 2005). However, skin trouble such as skin
rash, desquamation and itching, and digestive symptoms
such as diarrhea, nausea and liver enzyme elevation
emerge in higher rate (Forsythe and Faulkner 2004; Van
Zandwijk 2003). Skin rash is notorious as an adverse
event of EGFR-TKI and is noted in up to two-thirds ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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* There are some overlappings EGFR: Epidermal Growth Factor Receptor.
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only 5 to 10% (Jacot et al. 2004). Gefitinib, erlotinib and
cetuximab correlates between development of rash and
efficacy (Argiris and Mittal 2004; Cadranel et al. 2009;
Chiu et al. 2005; Janne et al. 2004; Stintzing et al. 2012;
Wacker et al. 2007; West et al. 2006). The most patients
of these studies were Caucasian, and there are very few
reports treating with Asian patients. Herein, we retro-
spectively assessed the relation between each adverse
event and efficacy of gefitinib.
Patients and methods
Patients
Present study was a retrospective analysis of all
patients with pathologically proven adenocarcinoma at
the Kanagawa National Hospital from January 2008 to
June 2012. All patients were Japanese whose ethnic
origins were Asian. Gefitinib was administered at a
dose of 250 mg daily to 24 patients with lung adeno-
carcinoma; 10 with post-operative recurrence and 14
inoperative advanced cases. There were 16 women and
8 men with ages ranging from 55 to 89 years (median:
67 years old) (Table 1). Informed consents of the
patients were obtained in accordance with institu-
tional guidance based on the Helsinki Declaration on
admission. The relevant institutional review board had
approved this study.
Methods
Follow-up assessments included physical examination,
complete blood counts, blood chemistry every 2–4 weeks
and tumor assessment by computed tomography were
done every 1–2 months.
Tumor response was assessed as complete response
(CR), partial response (PR), stable disease ≧12 weeks (SD)
or progressive disease (PD) in accordance with the stand-
ard Response Evaluation Criteria In Solid Tumours
(RECIST). Adverse events were evaluated and graded
using Common Terminology Criteria For Adverse Events
v4.0 (CTCAE). Skin rash and the grade were defined as
following criteria according to the CTCAE: grade 1, macu-
lar or popular eruption or erythema without associated
symptoms; grade 2, macular or popular eruption or ery-
thema with pruritus or other associated symptoms cover-
ing ≤50% of body surface; grade 3, symptomatic
generalized erythroderma or macular, popular or vesicular
eruption or desquamation covering >50% of body surface;
grade 4, generalized exfoliative dermatitis or ulcerative
dermatitis. After grade 3 adverse event emerged, the dose
of gefitinib was reduced to 250 mg on alternate days or
administration was discontinued.
Overall survival (OS) was evaluated for the period
from diagnosis as inoperative advanced lung cancer or
post-operatively recurrent lung cancer to the date ofdeath, referring to Dictionary Cancer Terms of the Na-
tional Cancer Institute. Kaplan-Meier survival curves
were drawn for OS, compared by means of Log-rank
test. For comparisons of proportions, chi-square test and
Fisher's exact test were used. All results were considered
significant at p-values of less than 0.05. All statistical
analysis was performed using the Stat Mate IV software
program version 4.01 (ATM, Inc, Bunkyo, Tokyo, Japan).
Results
Patient characteristics
From January 2008 to June 2012, gefitinib was adminis-
tered to 24 patients with lung adenocarcinoma; 10 with
Table 3 Objective response rate in cases administered





CR 2 0 2
PR 8 3 11
SD 0 4 4
PD 0 7 7
CR + PR (%) 10 (100) 3 (21.4) 13 (54.2)
RECIST Response Evaluation Criteria in Solid Tumors, CR Complete Response,
PR Partial Response, SD Stable Disease, PD Progressive Disease.
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cases. There were 16 women and 8 men with ages ran-
ging from 55 to 89 years (median: 67 years old). The
ethnic origin of all patients was Asian (Table 1).
The detail mutations of EGFR was that one case had
exon 18 G719X, 8 had in exon19 deletion, 7 had in exon
21 L858R, 3 did not have any EGFR mutations and 5
were not examined. In ECOG PS, 21cases were in PS 0–
1 and 3 were in PS 2–3.
Cases with previous chemotherapy were 10 and
chemotherapy naïve cases were 14. The regimen of the
previous chemotherapy was that 7 cases were adminis-
tered platinum anti-cancer agent and the third gener-
ation anti-cancer agent, a case were administered
gemcitabine (GEM) and vinorelbin (VNR), 2 cases were
given tegafur-uracil (UFT) as the first-line treatment, a
case was administered pemetrexed (PEM) and a case
was administered docetaxel (DTX) as the second-line
treatment.
Adverse events
In all 24 cases, skin trouble emerged in 10 cases (41.7%),
liver damage occurred in 9 cases (37.5%), diarrhea
emerged in 4 cases (16.7%) and acute lung injury
emerged in 2 cases (8.3%) (Table 2). The grade of each
case with skin rash was less than 2. Since the liver dam-
age was grade 3 in all 9 cases in CTAE, the dose was
reduced to the alternate days. The grade of each case
with diarrhea was also less than 2. Lung injury emerged
in 2 cases was grade 4 and they died.
Response to treatment and overall survival
Two patients achieved CR and 11 did PR. Four patients
resulted in SD and 7 did in PD as their best response.
The objective response rates (ORR) of all cases, cases
with skin rash and without skin rash were 54.2%, 100%
and 21.4% respectively (Table 3). Overall survival of the
cases with skin rash was significantly superior to the
cases without skin rash (p = 0.012, Figure 1).
Discussion
The response rate and adverse events have the ethnic
differences in gefitinib for advanced lung adenocarcin-
oma. For instance, the incidence of the EGFR mutation
is higher frequent in the Asian patients than the other
origin patients and ILD induced by gefitinib occurs moreTable 2 Adverse events after administration of gefinitib
(cases) Total (%)
Skin rash 10 (41.7)
Liver damage 9 (37.5)
Diarrhea 4 (16.7)
Acute lung injury 2 (8.3)frequently in Japan more than outside Japan (Ando et al.
2006; Jiang 2009; Kris et al. 2003; Kudoh et al. 2008;
Park and Goto 2006; Sequist et al. 2008; Shigematsu
et al. 2005; Tamura et al. 2008). On the other hand, the
correlation between development of rash and efficacy in
patients treated with erlotinib or cetuximab was demon-
strated in some reports (Stintzing et al. 2012; Wacker
et al. 2007). Dudek reported that skin rash and bronch-
ioalveolar histology correlates with clinical benefit in
patients with gefitinib as a therapy for previously treated
advanced or metastatic non-small cell lung cancer
(Dudek et al. 2006). However, the ethic population of
these reports was Caucasian and nobody knows whether
it is applicable for Japanese patients. We analyzed clin-
ical courses of Japanese patients of lung adenocarcinoma
in order to assess the relation between each adverse
event and efficacy of gefitinib, because gefitinib is one of
the first-line treatments for advanced non-small cell lung
cancer with EGFR mutation in guidelines of American
Society of Clinical Oncology (ASCO) (Keedy et al. 2011)
and the Japan Lung Cancer Society, and adenocarcinoma
is the most common pathological type in lung cancer
(Jemal et al. 2011).
We could indicate two significant evidences in Japanese
patients that skin rash predicted a good prognosis in the
patients of lung adenocarcinoma treated with gefitinib.
First of all, patients with skin rash achieved significantly
higher ORR than patients without skin rash in advanced
inoperative or postoperative recurrent lung adenocarcin-
oma treated with gefitinib (p = 0.001458, Table 4). Other
adverse events and ORR did not show relationship. In the
second, after following more than 2 years, overall survival
of the cases with skin rash was significantly superior to
the cases without skin rash (p = 0.012, Figure 1). From the
above, these analyses document the relationship between
skin rash during gefitinib therapy and improvements in
ORR and survival.
One important question is that why the skin rash
emerged on the normal skin of the patients of lung
Figure 1 Overall survival of advanced inoperative or postoperative recurrent lung adenocarcinoma patients with skin rash and without
skin rash.
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without EGFR mutation. Indeed, in this study, 3 cases
without EGFR mutation treated by gefitinib resulted in
PD and skin rash did not occurred at all. Francasso
reported that administration of single doses (250–500 mg/
m2) of cetuximab resulted in a dose-dependent decrease
in EGFR protein expression levels in skin (Fracasso et al.
2007). Biopsy of the lesions of skin rash induced by gefiti-
nib showed prominent keratin plugging in dilated infun-
dibula of hair follicles, a superficial purulent folliculitis
and disordered differentiation with focal parakeratosis
were seen (Albanell et al. 2002, Van Doorn et al. 2002).
These reports suggested that EGFR-TKI interrupted the
function of EGFR in not only tumor, but also on normal
skin, and consequently skin rash emerged.
In clinical practice of treating advanced lung cancer,
specimen of the tumor by transbronchial lung biopsy or
cell block of pleural effusion by thoracocentesis are oc-
casionally insufficient or inappropriate to detect EGFR
mutation (Aisner et al. 2011).The efficacy of the treat-
ment with gefitinib may be predictable in advance, if the
interaction between the skin and gefitinib in lung cancer
patients can be examined before initiating therapy. In
other words, skin biopsy would replace transbronchial
lung biopsy.Table 4 Relationship between each adverse event and
objective response rate
Skin rash Diarrhea Liver damage
+ - + - + -
CR, PR 10 3 2 11 6 7
SD, PD 0 11 2 9 3 8
p-value 0.001458 0.636 0.3001
CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive
Disease.In conclusion, ORR and OS of the advanced inopera-
tive or postoperative recurrent patients of lung adeno-
carcinoma with skin rash by gefitinib were significantly
superior to the cases without skin rash. Further exami-
nations are necessary in order to generalize our results
and hypothesis to clinical practice, because our study
population is small and our hospital is not a cancer cen-
ter but a general municipal hospital.
Conclusion
Skin rash by gefitinib for the advanced inoperative or
postoperative recurrent patients of lung adenocarcinoma
is a significant predictive factor of objective response
and prognosis.
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